Reviewing EyePoint Pharmaceuticals Inc. (EYPT)’s and Mustang Bio Inc. (NASDAQ:MBIO)’s results

Both EyePoint Pharmaceuticals Inc. (NASDAQ:EYPT) and Mustang Bio Inc. (NASDAQ:MBIO) are Biotechnology companies, competing one another. We will contrast their profitability, analyst recommendations, institutional ownership, risk, dividends, earnings and valuation.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
EyePoint Pharmaceuticals Inc. 4.57M 51.32 86.13M -1.35 0.00
Mustang Bio Inc. N/A 2292.45 34.49M -1.30 0.00

Table 1 highlights EyePoint Pharmaceuticals Inc. and Mustang Bio Inc.’s top-line revenue, earnings per share (EPS) and valuation.


Table 2 provides us the return on assets, net margins and return on equity of both companies.

Net Margins Return on Equity Return on Assets
EyePoint Pharmaceuticals Inc. -1,884.68% -414.6% -142.9%
Mustang Bio Inc. 0.00% -65.1% -60%


The current Quick Ratio of EyePoint Pharmaceuticals Inc. is 2.6 while its Current Ratio is 2.6. Meanwhile, Mustang Bio Inc. has a Current Ratio of 10.3 while its Quick Ratio is 10.3. Mustang Bio Inc. is better positioned to pay off its short-term and long-term debts than EyePoint Pharmaceuticals Inc.

Institutional and Insider Ownership

EyePoint Pharmaceuticals Inc. and Mustang Bio Inc. has shares held by institutional investors as follows: 62.3% and 9.6%. About 0.5% of EyePoint Pharmaceuticals Inc.’s share are held by insiders. Comparatively, Mustang Bio Inc. has 1.1% of it’s share held by insiders.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
EyePoint Pharmaceuticals Inc. -2.21% 21% 28.64% 25% 150% 40.21%
Mustang Bio Inc. -13.73% 1.34% -2.08% -45.36% -64.63% 28.23%

For the past year EyePoint Pharmaceuticals Inc. has stronger performance than Mustang Bio Inc.


Mustang Bio Inc. beats on 7 of the 9 factors EyePoint Pharmaceuticals Inc.

EyePoint Pharmaceuticals, Inc., a specialty biopharmaceutical company, engages in developing and commercializing ophthalmic products in indications with high unmet medical need to help improve the lives of patients with eye disorders. The company has developed three FDA-approved sustained-release treatments in ophthalmology, including DEXYCU (dexamethasone intraocular suspension), which is administered as a single intraocular dose at the end of ocular surgery for postoperative inflammation; ILUVIEN (fluocinolone acetonide intravitreal implant), a micro-insert for diabetic macular edema; and Retisert (fluocinolone acetonide intravitreal implant) for posterior uveitis. Its lead product candidate is Durasert, (fluocinolone acetonide intravitreal implant), a micro-insert for the treatment of non-infectious uveitis affecting the posterior segment of the eye. In addition, the company's pre-clinical development program focuses on using its core Durasert platform technology to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. It has license agreements with Bausch and Lomb for Retisert product; a license agreement with Alimera for ocular applications of the ILUVIEN device; and a collaboration agreement with Pfizer for the Durasert device delivering latanoprost. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was founded in 1987 and is headquartered in Watertown, Massachusetts.

Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel cancer immunotherapy products based on the chimeric antigen receptor engineered T cell technology. Its lead programs include MB-101 for the treatment of brain cancer that is in Phase I trials; and MB-102, a therapeutic agent in acute myeloid leukemia, which is in Phase I trials. The company was incorporated in 2015 and is based in New York, New York. Mustang Bio, Inc. is a subsidiary of Fortress Biotech, Inc.